Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612

Next Previous
X
Search
Trial Profile

A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Entacapone
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ND0612/003
  • Sponsors NeuroDerm

    • Most Recent Events

    • 08 Jun 2017 Pooled (n=46) results of NCT02096601 and NCT01883505 trials assessing levodopa pharmacokinetic profile derived from continuous subcutaneous (SC) administration of ND0612, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 28 Apr 2017 Results assessing levodopa pharmacokinetic profile after continuous subcutaneous administration of ND0612, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 19 Sep 2016 According to a NeuroDerm media release, data from the study will be presented at the 4th World Parkinson Congress (WPC) 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top